Boston, Greatbatch pump more cash into Intelect
This article was originally published in Clinica
Neuromodulation technology start-up Intelect Medical has secured additional funding of between $11-13.5m, as well as potential future milestone payments, from existing investors Boston Scientific and Greatbatch. The financing agreement with Boston also sees the company receive a co-exclusive licence to Intelect's Dimension visual programming software. According to Cleveland, Ohio-based Intelect, the new capital will be used to support ongoing R&D related to its deep brain stimulation (DBS) therapies and advance US and European clinical studies investigating the feasibility of the technology for traumatic brain injury and as a stroke recovery therapy. Boston and Greatbatch first became investors in Intelect in June 2007, when they injected $7m into the company's second financing round.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.